Stock Performance Overview
On 19 Aug 2026, Shree Ganesh Biotech India Ltd closed at ₹0.51, unchanged from the previous day’s close, while the Sensex declined by 0.27%. The stock has underperformed its sector by 0.29% on the day. Over the past week, the share price fell by 1.92%, compared to a 1.20% decline in the Sensex. The one-month performance shows a sharper drop of 5.56%, against the Sensex’s 1.44% fall.
Longer-term trends reveal a more pronounced decline. Over three months, the stock lost 13.56%, whereas the Sensex gained 2.43%. The one-year performance is particularly stark, with the stock down 34.62% compared to the Sensex’s 5.65% decline. Year-to-date, the stock has fallen 17.74%, while the Sensex dropped 9.61%. Over three and five years, the stock’s losses deepen to 50.49% and 92.42% respectively, contrasting with Sensex gains of 18.60% and 38.47% over the same periods. The ten-year performance remains flat at 0.00%, while the Sensex surged 174.35%.
Technical Indicators and Market Position
The technical outlook for Shree Ganesh Biotech India Ltd remains bearish. The current trend shifted to bearish on 16 Jun 2026 at ₹0.58, following a prior mildly bearish phase. The stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling persistent downward momentum.
Key technical levels include immediate support at ₹0.50, coinciding with the 52-week low, and immediate resistance at ₹0.54, near the 20-day moving average. Further resistance is noted at ₹0.59 (100 DMA) and ₹0.61 (200 DMA), with the 52-week high at ₹0.80 representing a distant hurdle.
Technical indicators such as MACD and KST are bearish on the weekly and monthly charts, while Bollinger Bands also suggest a bearish stance. The Relative Strength Index (RSI) currently shows no clear signal, indicating a lack of strong momentum either way.
Valuation and Financial Metrics
Shree Ganesh Biotech India Ltd is classified as a micro-cap company with a market capitalisation reflecting its modest scale. The stock’s valuation multiples highlight its current financial challenges. The Price to Book Value (P/BV) stands at 0.32x, indicating the market values the company at less than one-third of its book value. The EV/EBITDA and EV/EBIT ratios are both negative at -7.12x, reflecting losses at the earnings level. The EV/Sales ratio is 2.50x, while EV/Capital Employed is 0.22x.
The company is loss-making, with no Price to Earnings (P/E) or PEG ratios available. Dividend metrics are absent, with no dividend yield or payout reported.
Financial Performance and Profitability
Recent quarterly results reveal the company recorded its lowest Profit Before Depreciation, Interest and Tax (PBDIT) at ₹-0.89 crore and Profit Before Tax excluding Other Income (PBT Less OI) also at ₹-0.89 crore. Earnings Per Share (EPS) for the quarter stood at ₹-0.01, marking the lowest level recorded.
Over the past year, profits have declined sharply by 86%, contributing to the stock’s 34.62% negative return during the same period. The company reported a negative EBITDA of ₹-1.76 crore, underscoring ongoing earnings pressures.
Quality and Risk Assessment
The company’s overall quality grade is below average, reflecting its long-term financial performance. Key quality indicators include a 5-year sales decline of 31.22% and a 5-year EBIT contraction of 204.98%. The average EBIT to interest coverage ratio is weak at 0.35x, signalling limited ability to service debt obligations. Despite this, the company maintains a net cash position, with an average net debt to equity ratio of -0.12 and no promoter share pledging.
Return on Capital Employed (ROCE) and Return on Equity (ROE) are both weak, averaging 1.52% and 2.62% respectively, indicating low profitability relative to capital and shareholder funds. Institutional holdings remain minimal at 1.42%, with the majority of shares held by non-institutional investors.
Shareholding and Market Liquidity
Non-institutional shareholders constitute the majority ownership of Shree Ganesh Biotech India Ltd. Delivery volumes have shown some recent increase, with a 1-month delivery change of 27.05% and a 1-day delivery change of 10.12% compared to the 5-day average. The volume on 18 Aug 2026 was 6.57 lakh shares, representing 59.08% of total volume, higher than the trailing one-month average of 4.69 lakh shares.
Summary of Market Context
Shree Ganesh Biotech India Ltd’s stock has reached an unprecedented low point, reflecting a combination of subdued financial results, weak profitability metrics, and a bearish technical outlook. The stock’s performance has lagged significantly behind the broader market and sector indices across multiple time frames, highlighting the severity of its decline. Valuation multiples and quality assessments further illustrate the challenges faced by the company in maintaining earnings and shareholder value.
While the stock remains close to its 52-week low, it continues to trade below all major moving averages, with technical indicators predominantly bearish. The company’s financial metrics reveal persistent losses and limited capacity to generate returns on equity or capital employed. Shareholding patterns and delivery volumes suggest limited institutional interest, with non-institutional investors holding the majority stake.
Overall, the data portrays a company experiencing sustained downward pressure in its share price and financial performance, culminating in the recent all-time low on 19 Aug 2026.
